true
0001433607
0001433607
2025-07-30
2025-07-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September
7, 2025 (July 30, 2025)
InspireMD,
Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-35731
|
|
26-2123838 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
6303
Waterford District Drive, Suite 215
Miami,
Florida |
|
33126 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (888) 776-6804
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value per share |
|
NSPR |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Election of Directors
On
July 31, 2025, InspireMD, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) with
the Securities and Exchange Commission (“SEC”) announcing that its board of directors (the “Board”) appointed
Mr. Raymond W. Cohen to serve as a Class 3 director on the Board, with a term expiring at the Company’s 2026 annual meeting of
stockholders. At the time the Original Form 8-K was filed, the Board had not made a determination regarding any Board committee assignments
for Mr. Cohen.
On
September 7, 2025, the Board appointed Mr. Cohen to serve as a member of the Audit Committee and the Compensation Committee of
the Board.
This
Amendment No. 1 to the Original Form 8-K is being filed solely to report the Board committees to which Mr. Cohen has been appointed,
as required by the SEC. Except as set forth herein, the Original Form 8-K remains unchanged in all respects.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
INSPIREMD,
INC. |
| |
|
| Date: |
September
8, 2025 |
By: |
/s/
Marvin Slosman |
| |
Name: |
Marvin
Slosman |
| |
Title: |
Chief
Executive Officer |
